Is Fevertree’s share price a bargain after falling 30%?

Fevertree Drinks plc’s (LON: FEVR) share price has fallen 30%. Is now the time to buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Fevertree Drinks (LSE: FEVR) has generated spectacular returns for investors since its 2014 IPO. Listing at 137p, the shares surged as high 4,120p in September this year – a rise of an incredible 2,900%. Yet in the last six weeks or so, the share price has fallen sharply and the shares are currently changing hands for around 2,800p.

Does that price offer value? Let’s take a closer look as to whether now is the time to get on board this growth stock, after the recent 30% share price fall.

Growth story

I have to admit, I’ve been impressed by the growth story here. Almost every bar, pub and restaurant I’ve visited lately has served Fevertree mixers and there’s no doubt they have been a great hit with drinkers. I can see the appeal – if you’re spending money on premium spirits, you might as well pay for a premium mixer too, as around three-quarters of your drink is likely to be mixer.

Powerful growth

Looking at the financial performance, there’s no doubt it has grown rapidly in recent years and is still growing at a formidable pace. For example, in its half-year results in late July, Fevertree reported revenue growth of 45%, diluted earnings per share growth of 36% and an interim dividend hike of 40%. Management also advised that the outcome for the full year will be “comfortably ahead of its expectations.” Fevertree clearly has strong momentum at present and after recently signing a distribution agreement with SGWS – the largest North American wine and spirits distribution company – the growth story here looks like it could have further to run.

Valuation

But what about the valuation? FEVR has often traded at eye-wateringly high multiples in the past – is the situation any different now? 

Looking at consensus forecasts, analysts expect the group to generate earnings per share of 48.2p for the year ending 31 December. As such, the stock is currently trading on a forward-looking P/E ratio of 58.3, which is certainly high. That kind of valuation doesn’t leave much margin for error in my view. For example, if growth was to slow here in the UK or the US expansion experienced setbacks, the stock could come under further pressure. A P/E-to-growth (PEG) ratio of 2.5, while not outrageous, suggests that investors are certainly not buying growth at a bargain level.

Another ratio that concerns me is price-to-sales. Despite the recent share price fall, the group’s market capitalisation is still large at £3.15bn. With analysts forecasting sales of £225.7m for FY2018, the price-to-sales ratio on a forward-looking basis is 13.96, which is also quite high. So FEVR’s valuation is clearly quite expensive, even after the share price drop.

Brand power

The other issue that concerns me is the company’s competitive advantage and more specifically, the power of the brand. Yes, Fevertree has great-tasting products, but is there anything to stop rivals entering the market with fancy new mixers and stealing market share? To my mind, it doesn’t yet have the brand power of a Coco-Cola or a Sprite that could help it protect its profitability.

Overall, I have concerns regarding the investment case here, mainly on valuation grounds. As such, I’ll be keeping Fevertree on my watchlist for now and waiting to see how things unfold.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no shares in any companies mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Senior woman potting plant in garden at home
Investing Articles

£500 to invest a month? Here’s how a Stocks and Shares ISA could unlock a comfortable retirement

The tax benefits of the Stocks and Shares ISA can provide the foundations for significant long-term wealth creation. Here's how.

Read more »

Young female hand showing five fingers.
Investing Articles

5 reasons to consider buying this FTSE 100 stock like there’s no tomorrow

Ben McPoland highlights five reasons why he thinks this excellent FTSE 100 stock looks like a solid portfolio contender right…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Down 83%! This FTSE 250 firm could now be a stock market takeover target

After a serious stock market slump, the boss of this FTSE 250 biotech company has reportedly highlighted its takeover exposure.

Read more »

Investing Articles

This has to be one of the best UK stocks to buy, IMO! Here’s what the charts say

UK stocks are often considered undervalued, but very few appear to come close to this one. Dr James Fox explains…

Read more »

Investing Articles

Forecast: in 12 months, the Barclays share price could be…

The Barclays share price has surged over the past 12 months, but where will it go next? Dr James Fox…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

1 top stock offering incredible value right now!

After its recent decline, this high-quality tech share benefitting from artificial intelligence is trading more like a value stock.

Read more »

The Troat Inn on River Cherwell in Oxford. England
Investing Articles

Down 21% in 6 months! Should I buy the dip in this FTSE 250 stock?

Ben McPoland is wondering whether he should add struggling FTSE 250 share JD Wetherspoon to his Stocks and Shares ISA…

Read more »

Investing Articles

As the ISA deadline looms, here are 2 dividend-paying stocks I have been loading up on

With the opportunity to invest up to £20,000 in an ISA available, Andrew Mackie looks at two of his favourite…

Read more »